A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria

Citations Over TimeTop 1% of 2006 papers

Abstract

Progerias are rare genetic diseases characterized by premature aging. Several progeroid disorders are caused by mutations that lead to the accumulation of a lipid-modified (farnesylated) form of prelamin A, a protein that contributes to the structural scaffolding for the cell nucleus. In progeria, the accumulation of farnesyl-prelamin A disrupts this scaffolding, leading to misshapen nuclei. Previous studies have shown that farnesyltransferase inhibitors (FTIs) reverse this cellular abnormality. We tested the efficacy of an FTI (ABT-100) in Zmpste24-deficient mice, a mouse model of progeria. The FTI-treated mice exhibited improved body weight, grip strength, bone integrity, and percent survival at 20 weeks of age. These results suggest that FTIs may have beneficial effects in humans with progeria.

Related Papers

• → Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson–Gilford progeria syndrome mutation(2005)305 cited
• → Hutchinson–Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody(2006)195 cited
• → Molecular insights into the premature aging disease progeria(2016)109 cited
• → Lamin A-linked progerias: is farnesylation the be all and end all?(2010)13 cited
• → Progeria Research Day at Brunel University(2011)2 cited